ISSN: 2008-2258
Vol 15, No 2 (2022): Spring
Multi-stage analysis of FOXM1, PYROXD1, hTERT, PPARA, PIM3, BMI1 and MCTP1 expression patterns in colorectal cancer
Gastroenterology and Hepatology from Bed to Bench,
,
https://doi.org/10.22037/ghfbb.vi.2304
Abstract
Purpose: To explore biomarkers with a tumor stage-dependent expression pattern in patients with colorectal cancer (CRC). Methods: Real-time RT-PCR was used to investigate the expression patterns of the FOXM1, PYROXD1, hTERT, BMI, PPARA, PIM3 and MCTP1 genes in 54 patients with stage I to IV CRC and their relation with clinicopathological features of CRC were analyzed. Results: FOXM1, hTERT and MCTP1 genes are overexpressed in CRC tumor tissues when compared to normal adjacent tissues in all the stages. FOXM1, PYROXD1, hTERT, PIM3, BMI1, PPARA and MCTP1 had-stage dependent expression. Investigation of the association between clinicopathological features and expression pattern of the studied genes revealed; a) a significant relationship between FOXM1 gene expression level and tumor stage, tumor size and lymph node involvement, b) a considerable association between alterations in PPARA and PIM3 expression and lymph node involvement, c) a notable correlation between hTERT expression level and the tumor stage and d) a strong correlation between MCTP1 expression and patient's age only. Conclusion: Our study indicates that expression profiles of these genes either individually or together can be applied as potential biomarkers for prognosis of CRC"
Keywords:
- Colorectal Cancer
- Expression Pattern
- Real-time RT-PCR
References
1. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer. 2010;2.
2. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2016:gutjnl-2015-310912.
3. Alireza S, Mehdi N, Ali M, Alireza M, Reza M, Parkin D. Cancer occurrence in Iran in 2002, an international perspective. Asian Pacific journal of cancer prevention. 2005;6(3):359.
4. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Annals of surgical oncology. 2010;17(6):1471-4.
5. Ohori M, Wheeler TM, Scardino PT. The new American joint committee on cancer and international union against cancer TNM classification of prostate cancer. Cancer. 1994;74(1):104-14.
6. Sarver AL, French AJ, Borralho PM, Thayanithy V, Oberg AL, Silverstein KA, et al. Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC cancer. 2009;9(1):401.
7. Lepourcelet M, Tou L, Cai L, Sawada J-i, Lazar AJ, Glickman JN, et al. Insights into developmental mechanisms and cancers in the mammalian intestine derived from serial analysis of gene expression and study of the hepatoma-derived growth factor (HDGF). Development. 2005;132(2):415-27.
8. Maak M, Simon I, Nitsche U, Roepman P, Snel M, Glas AM, et al. Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. Annals of surgery. 2013;257(6):1053-8.
9. Sobin LH, Compton CC. TNM seventh edition: what's new, what's changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer. Cancer. 2010;116(22):5336-9.
10. Shabani S, Mahjoubi F, Mahjoubi B, Mirzaee R. Investigation of hTERT Expression Level and its Relation with Clinicopathological Features and Resistance to Chemotherapy in Colorectal Cancer Patients. Journal of Molecular Biomarkers & Diagnosis. 2014;5(3):1.
11. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D. GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC cancerbase no. 10. Lyon, France: International Agency for Research on Cancer; 2010. Disponible en: URL: http://globocan iarc fr. 2011.
12. Mahmodlou R, Mohammadi P, Sepehrvand N. Colorectal cancer in northwestern Iran. ISRN gastroenterology. 2012;2012.
13. Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A, et al. Molecular staging for survival prediction of colorectal cancer patients. Journal of Clinical Oncology. 2005;23(15):3526-35.
14. Nannini M, Pantaleo MA, Maleddu A, Astolfi A, Formica S, Biasco G. Gene expression profiling in colorectal cancer using microarray technologies: results and perspectives. Cancer treatment reviews. 2009;35(3):201-9.
15. Wooi CS, Hang ESU, editors. Overexpression of Wildtype Periostin and Transforming Growth Factor Beta I Genes in Colorectal Carcinoma: A Preliminary Study. Selected Articles from the 7th National Genetics Congress 2007; 2009.
16. Wierstra I, Alves J. FOXM1, a typical proliferation-associated transcription factor. Biological chemistry. 2007;388(12):1257-74.
17. Kalin TV, Ustiyan V, Kalinichenko VV. Multiple faces of FoxM1 transcription factor: lessons from transgenic mouse models. Cell cycle. 2011;10(3):396-405.
18. Koo C-Y, Muir KW, Lam EW-F. FOXM1: From cancer initiation to progression and treatment. Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms. 2012;1819(1):28-37.
19. Huang C, Du J, Xie K. FOXM1 and its oncogenic signaling in pancreatic cancer pathogenesis. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2014;1845(2):104-16.
20. Zhang J, Zhang K, Zhou L, Wu W, Jiang T, Cao J, et al. Expression and potential correlation among Forkhead box protein M1, Caveolin-1 and E-cadherin in colorectal cancer. Oncology letters. 2016;12(4):2381-8.
21. Chu X-Y, Zhu Z-M, Chen L-B, Wang J-H, Su Q-S, Yang J-R, et al. FOXM1 expression correlates with tumor invasion and a poor prognosis of colorectal cancer. Acta histochemica. 2012;114(8):755-62.
22. Bellelli R, Castellone MD, Garcia-Rostan G, Ugolini C, Nucera C, Sadow PM, et al. FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma. Endocrine-related cancer. 2012;19(5):695-710.
23. Sher T, Yi HF, McBride OW, Gonzalez FJ. cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry. 1993;32(21):5598-604.
24. Michalik L, Desvergne B, Wahli W. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nature Reviews Cancer. 2004;4(1):61.
25. Rakhshandehroo M, Sanderson LM, Matilainen M, Stienstra R, Carlberg C, De Groot PJ, et al. Comprehensive analysis of PPARα-dependent regulation of hepatic lipid metabolism by expression profiling. PPAR research. 2007;2007.
26. Sanderson LM, de Groot PJ, Hooiveld GJ, Koppen A, Kalkhoven E, Müller M, et al. Effect of synthetic dietary triglycerides: a novel research paradigm for nutrigenomics. PloS one. 2008;3(2):e1681.
27. Tan IB, Tan P. Genetics: an 18-gene signature (ColoPrint®) for colon cancer prognosis. Nature Reviews Clinical Oncology. 2011;8(3):131.
28. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science. 1997;277(5328):955-9.
29. Bertorelle R, Briarava M, Rampazzo E, Biasini L, Agostini M, Maretto I, et al. Telomerase is an independent prognostic marker of overall survival in patients with colorectal cancer. British journal of cancer. 2013;108(2):278.
30. Mukaida N, Wang YY, Li YY. Roles of Pim‐3, a novel survival kinase, in tumorigenesis. Cancer science. 2011;102(8):1437-42.
31. Zheng H-C, Tsuneyama K, Takahashi H, Miwa S, Sugiyama T, Popivanova BK, et al. Aberrant Pim-3 expression is involved in gastric adenoma–adenocarcinoma sequence and cancer progression. Journal of cancer research and clinical oncology. 2008;134(4):481-8.
32. Popivanova BK, Li YY, Zheng H, Omura K, Fujii C, Tsuneyama K, et al. Proto‐oncogene, Pim‐3 with serine/threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent Bad‐mediated apoptosis. Cancer science. 2007;98(3):321-8.
33. Li Y-Y, Popivanova BK, Nagai Y, Ishikura H, Fujii C, Mukaida N. Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines. Cancer research. 2006;66(13):6741-7.
34. Zhu S, Zhao D, Yan L, Jiang W, Kim J-S, Gu B, et al. BMI1 regulates androgen receptor in prostate cancer independently of the polycomb repressive complex 1. Nature communications. 2018;9(1):500.
35. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. nature. 2003;423(6937):255.
36. Gray F, Cho HJ, Shukla S, He S, Harris A, Boytsov B, et al. BMI1 regulates PRC1 architecture and activity through homo-and hetero-oligomerization. Nature communications. 2016;7:13343.
37. Shin O-H, Han W, Wang Y, Südhof TC. Evolutionarily conserved multiple C2 domain proteins with two transmembrane regions (MCTPs) and unusual Ca2+ binding properties. Journal of Biological Chemistry. 2005;280(2):1641-51.
38. Berridge MJ, Lipp P, Bootman MD. The versatility and universality of calcium signalling. Nature reviews Molecular cell biology. 2000;1(1):11.
2. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2016:gutjnl-2015-310912.
3. Alireza S, Mehdi N, Ali M, Alireza M, Reza M, Parkin D. Cancer occurrence in Iran in 2002, an international perspective. Asian Pacific journal of cancer prevention. 2005;6(3):359.
4. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Annals of surgical oncology. 2010;17(6):1471-4.
5. Ohori M, Wheeler TM, Scardino PT. The new American joint committee on cancer and international union against cancer TNM classification of prostate cancer. Cancer. 1994;74(1):104-14.
6. Sarver AL, French AJ, Borralho PM, Thayanithy V, Oberg AL, Silverstein KA, et al. Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC cancer. 2009;9(1):401.
7. Lepourcelet M, Tou L, Cai L, Sawada J-i, Lazar AJ, Glickman JN, et al. Insights into developmental mechanisms and cancers in the mammalian intestine derived from serial analysis of gene expression and study of the hepatoma-derived growth factor (HDGF). Development. 2005;132(2):415-27.
8. Maak M, Simon I, Nitsche U, Roepman P, Snel M, Glas AM, et al. Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. Annals of surgery. 2013;257(6):1053-8.
9. Sobin LH, Compton CC. TNM seventh edition: what's new, what's changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer. Cancer. 2010;116(22):5336-9.
10. Shabani S, Mahjoubi F, Mahjoubi B, Mirzaee R. Investigation of hTERT Expression Level and its Relation with Clinicopathological Features and Resistance to Chemotherapy in Colorectal Cancer Patients. Journal of Molecular Biomarkers & Diagnosis. 2014;5(3):1.
11. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D. GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC cancerbase no. 10. Lyon, France: International Agency for Research on Cancer; 2010. Disponible en: URL: http://globocan iarc fr. 2011.
12. Mahmodlou R, Mohammadi P, Sepehrvand N. Colorectal cancer in northwestern Iran. ISRN gastroenterology. 2012;2012.
13. Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A, et al. Molecular staging for survival prediction of colorectal cancer patients. Journal of Clinical Oncology. 2005;23(15):3526-35.
14. Nannini M, Pantaleo MA, Maleddu A, Astolfi A, Formica S, Biasco G. Gene expression profiling in colorectal cancer using microarray technologies: results and perspectives. Cancer treatment reviews. 2009;35(3):201-9.
15. Wooi CS, Hang ESU, editors. Overexpression of Wildtype Periostin and Transforming Growth Factor Beta I Genes in Colorectal Carcinoma: A Preliminary Study. Selected Articles from the 7th National Genetics Congress 2007; 2009.
16. Wierstra I, Alves J. FOXM1, a typical proliferation-associated transcription factor. Biological chemistry. 2007;388(12):1257-74.
17. Kalin TV, Ustiyan V, Kalinichenko VV. Multiple faces of FoxM1 transcription factor: lessons from transgenic mouse models. Cell cycle. 2011;10(3):396-405.
18. Koo C-Y, Muir KW, Lam EW-F. FOXM1: From cancer initiation to progression and treatment. Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms. 2012;1819(1):28-37.
19. Huang C, Du J, Xie K. FOXM1 and its oncogenic signaling in pancreatic cancer pathogenesis. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2014;1845(2):104-16.
20. Zhang J, Zhang K, Zhou L, Wu W, Jiang T, Cao J, et al. Expression and potential correlation among Forkhead box protein M1, Caveolin-1 and E-cadherin in colorectal cancer. Oncology letters. 2016;12(4):2381-8.
21. Chu X-Y, Zhu Z-M, Chen L-B, Wang J-H, Su Q-S, Yang J-R, et al. FOXM1 expression correlates with tumor invasion and a poor prognosis of colorectal cancer. Acta histochemica. 2012;114(8):755-62.
22. Bellelli R, Castellone MD, Garcia-Rostan G, Ugolini C, Nucera C, Sadow PM, et al. FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma. Endocrine-related cancer. 2012;19(5):695-710.
23. Sher T, Yi HF, McBride OW, Gonzalez FJ. cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry. 1993;32(21):5598-604.
24. Michalik L, Desvergne B, Wahli W. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nature Reviews Cancer. 2004;4(1):61.
25. Rakhshandehroo M, Sanderson LM, Matilainen M, Stienstra R, Carlberg C, De Groot PJ, et al. Comprehensive analysis of PPARα-dependent regulation of hepatic lipid metabolism by expression profiling. PPAR research. 2007;2007.
26. Sanderson LM, de Groot PJ, Hooiveld GJ, Koppen A, Kalkhoven E, Müller M, et al. Effect of synthetic dietary triglycerides: a novel research paradigm for nutrigenomics. PloS one. 2008;3(2):e1681.
27. Tan IB, Tan P. Genetics: an 18-gene signature (ColoPrint®) for colon cancer prognosis. Nature Reviews Clinical Oncology. 2011;8(3):131.
28. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science. 1997;277(5328):955-9.
29. Bertorelle R, Briarava M, Rampazzo E, Biasini L, Agostini M, Maretto I, et al. Telomerase is an independent prognostic marker of overall survival in patients with colorectal cancer. British journal of cancer. 2013;108(2):278.
30. Mukaida N, Wang YY, Li YY. Roles of Pim‐3, a novel survival kinase, in tumorigenesis. Cancer science. 2011;102(8):1437-42.
31. Zheng H-C, Tsuneyama K, Takahashi H, Miwa S, Sugiyama T, Popivanova BK, et al. Aberrant Pim-3 expression is involved in gastric adenoma–adenocarcinoma sequence and cancer progression. Journal of cancer research and clinical oncology. 2008;134(4):481-8.
32. Popivanova BK, Li YY, Zheng H, Omura K, Fujii C, Tsuneyama K, et al. Proto‐oncogene, Pim‐3 with serine/threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent Bad‐mediated apoptosis. Cancer science. 2007;98(3):321-8.
33. Li Y-Y, Popivanova BK, Nagai Y, Ishikura H, Fujii C, Mukaida N. Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines. Cancer research. 2006;66(13):6741-7.
34. Zhu S, Zhao D, Yan L, Jiang W, Kim J-S, Gu B, et al. BMI1 regulates androgen receptor in prostate cancer independently of the polycomb repressive complex 1. Nature communications. 2018;9(1):500.
35. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. nature. 2003;423(6937):255.
36. Gray F, Cho HJ, Shukla S, He S, Harris A, Boytsov B, et al. BMI1 regulates PRC1 architecture and activity through homo-and hetero-oligomerization. Nature communications. 2016;7:13343.
37. Shin O-H, Han W, Wang Y, Südhof TC. Evolutionarily conserved multiple C2 domain proteins with two transmembrane regions (MCTPs) and unusual Ca2+ binding properties. Journal of Biological Chemistry. 2005;280(2):1641-51.
38. Berridge MJ, Lipp P, Bootman MD. The versatility and universality of calcium signalling. Nature reviews Molecular cell biology. 2000;1(1):11.
- Abstract Viewed: 0 times
